A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants
Cancer Medicine · 2023-09 · 12 (18) · 19225-19233
DOI: 10.1002/cam4.6527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.09.2023. Verfasst von Kutluk H Oktay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, NCATS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Better tools for post‐chemotherapy amenorrhea risk assessment are needed for fertility preservation decision‐making. Our aim was to determine the predictors of amenorrhea risk at 12 and 18 months post‐chemotherapy in women with breast cancer.
Methods
142 women with breast cancer were longitudinally followed for their menstrual changes at 6, 12, and 18 months after the completion of adjuvant chemotherapy with an Anthracycline‐Cyclophosphamide‐based (AC‐based) or Cyclophosphamide‐Methotrexate +5‐Fluorouracil regimen. Pre‐ and/or post‐chemo AMH levels, age, BMI, tamoxifen use, regimen type, and germline BRCA pathogenic variant ( gBRCApv ) status were evaluated for the prediction of amenorrhea at 6–18 months.
Results
In multivariable‐adjusted logistic regression, age ( p = 0.03) and AMH ( p = 0.03) at 12 months, and gBRCApv status ( p = 0.03) at 18 months were significant predictors of amenorrhea (areas under the ROC curve of 0.77 and 0.76, for 12 and 18 months, respectively) among 102 evaluable subjects. An undetectable AMH immediately post‐chemotherapy was predictive of amenorrhea with 2.0 ng/mL group showed attenuated time‐trend risk of amenorrhea versus AMH ≤2.0 group (ratio of ORs = 0.91, 95% CI = 0.86–0.97, p = 0.002), while the gBRCApv + showed a steeper time trend, versus the controls (ratio of ORs = 1.12, 95% CI = 1.04–1.20, p = 0.003).
Conclusions
In addition to the pre‐ and post‐treatment AMH levels, gBRCApv status is a novel potential predictor of amenorrhea at 12 and 18 months after chemotherapy. The higher likelihood of amenorrhea in women gBRCApv suggests that they are more prone to losing their fertility post‐chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Obstetrics and Gynecology, Istanbul Health and Technology University School of Medicine, Istanbul, Turkey.
- Department of Obstetrics and Gynecology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto, Brazil.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.
- Weill Cornell Medical Center, New York, New York, USA.
ORCID-Profile: Kutluk H Oktay
Förderung
- NCI NIH HHS
- NICHD NIH HHS
- NCATS NIH HHS
- National Institute of Child Health and Human Development
Zitieren
APA
Oktay, K. H., Turan, V., Bedoschi, G., Abdo, N., Bang, H., & Goldfarb, S. (2023). A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants. Cancer Medicine, 12(18), 19225-19233. https://doi.org/10.1002/cam4.6527
Vancouver
Oktay KH, Turan V, Bedoschi G, Abdo N, Bang H, Goldfarb S. A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants. Cancer Medicine. 2023;12(18):19225-19233. doi:10.1002/cam4.6527
BibTeX
@article{Oktay2023,
author = {Oktay, Kutluk H and Turan, Volkan and Bedoschi, Giuliano and Abdo, Nadia and Bang, Heejung and Goldfarb, Shari},
title = {A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {18},
pages = {19225--19233},
doi = {10.1002/cam4.6527}
}
EUVIMED